Hormonal therapy of pancreatic carcinoma - Rationale and perspectives

Daniele Perilli, Carlo Mansi, Vincenzo Savarino, Guido Celle

Research output: Contribution to journalArticlepeer-review


Exocrine pancreas carcinoma is still diagnosed at a relatively late stage, so that only a few cases can be cured by surgery. Therefore, it is desirable that an effective medical therapy be found first to stall the development of the disease and second to improve the life conditions of patients. On the basis of recent discoveries, a new therapeutic approach seems to derive from hormone manipulation. The growth of pancreatic carcinoma appears to be stimulated by various factors, such as Epidermal Growth Factor (EGF) and Insulin-like Growth Factor I (IGF-I), and by various hormones, such as androgens and cholecystokinin. Several studies performed on cell lines and on animal models of pancreatic carcinoma demonstrated an antitumoral effect of certain antihormones and of somatostatin. Taking such studies as a premise, the first clinical studies were finally started in patients suffering from nonoperable pancreatic cancer. Results are still partial and contradictory, but such research is certainly worthy of further study along the lines already taken.

Original languageEnglish
Pages (from-to)159-168
Number of pages10
JournalInternational Journal of Pancreatology
Issue number3
Publication statusPublished - Jun 1993


  • Gastrointestinal hormones
  • growth factors
  • sex hormones
  • somatostatin

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Endocrinology


Dive into the research topics of 'Hormonal therapy of pancreatic carcinoma - Rationale and perspectives'. Together they form a unique fingerprint.

Cite this